The bispecific antibody targeted in this project, NN4101, is intended for the treatment of retinal neovascular diseases, in which abnormal blood vessel formation in the retina leads to vision impairment. As a “first-in-class” medicine with a novel mechanism of action distinct from conventional therapies, it has the potential to provide a new treatment option. At the same time, the structural complexity of bispecific antibodies requires advanced technologies and stringent quality control across both process development and manufacturing.
Through seamless technology transfer from the Copenhagen facility to the Chiba facility, AGC Biologics has established an integrated framework that supports both process development and GMP manufacturing. Leveraging its network of cGMP-compliant facilities^*4 across Japan, the United States, and Europe, the company maximizes synergies across its global operations. This enables AGC Biologics to provide flexible manufacturing solutions tailored to customers’ development and production needs by utilizing the most appropriate facility within its network.

Under its medium-term management plan, AGC plus-2026 , the AGC Group has identified “Well-being” as one of the key social values to be created through its products and technologies. Going forward, AGC will continue to provide high-quality process development and manufacturing services globally across a wide range of modalities, contributing to safe, secure, and healthy lives for people around the world through its life science business.

Notes

AGC Group CDMO business sites and supported modalities